Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma

Christian Karime, Jing Wang, Gregory Woodhead, Kabir Mody, Charles T. Hennemeyer, Mitesh J. Borad, Daruka Mahadevan, Sreenivasa R. Chandana, Hani Babiker

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
JournalExpert Opinion on Investigational Drugs
DOIs
StateAccepted/In press - 2021

Keywords

  • Immunomodulation
  • immunotherapy
  • refractory cancer
  • tilsotolimod
  • toll-like receptor 9

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma'. Together they form a unique fingerprint.

Cite this